Sleep disorders are one of the most frequent reasons for consultation in pediatrics, with a prevalence that ranges between 13-27% according to the different series consulted, referring to children aged between 4 and 12 years. On the other hand, its participation is well known as a comorbidity in children who are diagnosed, according to criteria established by the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of an attention deficit disorder and / or hyperactivity (ADHD), with which it is associated in up to 55% of cases. Comorbidity that can be primary, but that can sometimes be secondary to the effect of psychostimulant medication (Methylphenidate / MTF). Currently, new compounds with fewer adverse effects are being developed and tested as possible therapies for ADHD and its comorbidities, including omega (ω) -3 fatty acids for their possible cognitive and learning benefits, and melatonin for its sleep inducing effects, synchronization of biological rhythms and neuronal protection. With this background we set out in this project the objectives that we describe below: a) Define sleep-wake patterns and their relationship with the circadian variation in the excretion of 6-sulfate oxymelatonin (6s-aMT) in urine in 2 groups of patients. A group of normal children, without endocrine or sleep disorders (Control Group: GC), and another group of children with various sleep disorders, according to the International Classification of Sleep Disorders (CITS) (Group with Sleep Disorders: G-TS). b) To verify the utility of a therapeutic trial with melatonin in those G-TS patients in whom a low production of 6s-aMT or an alteration in its secretion was demonstrated. c) To evaluate the therapeutic efficacy and short-term safety profile of a combined treatment of MTF, melatonin and ω-3 fatty acids in a sample of ADHD patients, monitoring the serum fatty acid profile and the changes experienced in the pattern of sleep through actigraphy and the application of a neural network model. b) To verify the utility of a therapeutic trial with melatonin in those G-TS patients in whom a low production of 6s-aMT or an alteration in its secretion was demonstrated. c) To evaluate the therapeutic efficacy and the short-term safety profile of a combined treatment of MTF, melatonin and ω-3 fatty acids in a sample of ADHD patients, monitoring the serum fatty acid profile and the changes experienced in the pattern of sleep through actigraphy and the application of a neural network model. b) To verify the utility of a therapeutic trial with melatonin in those G-TS patients in whom a low production of 6s-aMT or an alteration in its secretion was demonstrated. c) To evaluate the therapeutic efficacy and short-term safety profile of a combined treatment of MTF, melatonin and ω-3 fatty acids in a sample of ADHD patients, monitoring the serum fatty acid profile and the changes experienced in the pattern of sleep through actigraphy and the application of a neural network model.

Direct Link: http://hdl.handle.net/10481/48884

Journal: Thesis

Keywords: ADHD, children, melatonin, omega-3 fatty acids, psychophysiology, Sleep,

Applications: Sleep,

CamNtech Reference: M17050

Back to Search Results

UK & International customers

CamNtech Ltd.
Manor Farm
Fenstanton
Cambridgeshire
PE28 9JD, UK

US customers

CamNtech Inc.
630 Boerne Stage Airfield,
Boerne,
Texas 78006,
USA

Copyright

© 2020 CamNtech Ltd and CamNtech Inc

Company information

Registered in England No. 2221302
VAT No: GB486 3019 34


Privacy Policy